{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:26:14Z","timestamp":1789579574762,"version":"build-2803163510"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001027","name":"Australian Government\u2019s Department of Health and Ageing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>People experiencing homelessness are disproportionately affected by hepatitis C virus (HCV) infection compared with housed populations. Surveillance for HCV reinfection after successful treatment is a critical step in the care cascade, but limited data on reinfection are available among this highly marginalized group. This study assessed posttreatment reinfection risk in a real-world cohort of homeless-experienced individuals in Boston.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Individuals receiving HCV direct-acting antiviral treatment through Boston Health Care for the Homeless Program during 2014\u20132020 with posttreatment follow-up assessment were included. Reinfection was identified based on recurrent HCV RNA at 12 weeks posttreatment with HCV genotype switch or any recurrent HCV RNA following sustain virologic response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 535 individuals were included (81% male, median age 49 years, 70% unstably housed or homeless at treatment initiation). Seventy-four HCV reinfections were detected, including 5 second reinfections. HCV reinfection rate was 12.0\/100 person-years (95% confidence interval [CI]: 9.5\u201315.1) overall, 18.9\/100 person-years (95% CI: 13.3\u201326.7) among individuals with unstable housing and 14.6\/100 person-years (95% CI: 10.0\u201321.3) among those experiencing homelessness. In adjusted analysis, experiencing homelessness (vs stable housing, adjusted hazard ratio, 2.14; 95% CI: 1.09\u20134.20; P = .026) and drug use within 6 months before treatment (adjusted hazard ratio, 5.23; 95% CI: 2.25\u201312.13; P &amp;lt; .001) were associated with increased reinfection risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found high HCV reinfection rates in a homeless-experienced population, with increased risk among those homeless at treatment. Tailored strategies to address the individual and systems factors impacting marginalized populations are required to prevent HCV reinfection and to enhance engagement in posttreatment HCV care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad127","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T07:37:31Z","timestamp":1677915451000},"page":"46-55","source":"Crossref","is-referenced-by-count":10,"title":["Hepatitis C Virus Reinfection in a Real-World Cohort of Homeless-Experienced Individuals in Boston"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6599-9925","authenticated-orcid":false,"given":"Marguerite E","family":"Beiser","sequence":"first","affiliation":[{"name":"Institute for Research, Quality, and Policy in Homeless Health Care, Boston Health Care for the Homeless Program , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah C","family":"Shaw","sequence":"additional","affiliation":[{"name":"Institute for Research, Quality, and Policy in Homeless Health Care, Boston Health Care for the Homeless Program , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savanna K","family":"Shores","sequence":"additional","affiliation":[{"name":"Institute for Research, Quality, and Policy in Homeless Health Care, Boston Health Care for the Homeless Program , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M","family":"Carson","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Hajarizadeh","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"key":"2024111411415409300_ciad127-B1","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"2024111411415409300_ciad127-B2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/cid\/cix295","article-title":"Prevalence of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus among homeless and nonhomeless United States veterans","volume":"65","author":"Noska","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024111411415409300_ciad127-B3","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/jvh.12936","article-title":"Hepatitis C among vulnerable populations: a seroprevalence study of homeless, people who inject drugs and prisoners in London","volume":"25","author":"Aisyah","year":"2018","journal-title":"J Viral Hepat"},{"key":"2024111411415409300_ciad127-B4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1473-3099(12)70177-9","article-title":"Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis","volume":"12","author":"Beijer","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2024111411415409300_ciad127-B5","doi-asserted-by":"crossref","first-page":"108525","DOI":"10.1016\/j.drugalcdep.2021.108525","article-title":"Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington","volume":"220","author":"Corcorran","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2024111411415409300_ciad127-B6","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102714","article-title":"Individual and network factors associated with HCV treatment uptake among people who inject drugs","volume":"78","author":"Falade-Nwulia","year":"2020","journal-title":"Int J Drug Policy"},{"key":"2024111411415409300_ciad127-B7","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/cid\/ciaa571","article-title":"Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage study","volume":"73","author":"Valerio","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024111411415409300_ciad127-B8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.drugpo.2019.03.017","article-title":"Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston","volume":"72","author":"Beiser","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2024111411415409300_ciad127-B9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12954-021-00486-4","article-title":"Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City","volume":"18","author":"Ziff","year":"2021","journal-title":"Harm Reduct J"},{"key":"2024111411415409300_ciad127-B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07778-w","article-title":"Factors associated with sustained virologic response to hepatitis C treatment in a homeless-experienced cohort in Boston, 2014\u20132020","author":"Beiser","year":"2022","journal-title":"J Gen Intern Med"},{"key":"2024111411415409300_ciad127-B11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10900-018-0568-z","article-title":"Successful implementation of a shared medical appointment model for hepatitis C treatment at a community health center","volume":"44","author":"Hodges","year":"2019","journal-title":"J Commu Health"},{"key":"2024111411415409300_ciad127-B12","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/jvh.13175","article-title":"Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection","volume":"26","author":"Read","year":"2019","journal-title":"J Viral Hepat"},{"key":"2024111411415409300_ciad127-B13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/jvh.13240","article-title":"High rate of hepatitis C reinfection following antiviral treatment in the North East England prisons","volume":"27","author":"Bhandari","year":"2020","journal-title":"J Viral Hepat"},{"key":"2024111411415409300_ciad127-B14","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1093\/cid\/ciaa253","article-title":"Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people who inject drugs","volume":"72","author":"Cunningham","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024111411415409300_ciad127-B15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jvh.12666","article-title":"HCV reinfection incidence among individuals treated for recent infection","volume":"24","author":"Martinello","year":"2017","journal-title":"J Viral Hepat"},{"key":"2024111411415409300_ciad127-B16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.drugpo.2019.06.016","article-title":"High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units","volume":"72","author":"Valencia","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2024111411415409300_ciad127-B17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2021.09.038","article-title":"Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs","volume":"76","author":"Yeung","year":"2022","journal-title":"J Hepatol"},{"key":"2024111411415409300_ciad127-B18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/cid\/ciac246","article-title":"Hepatitis C virus reinfection following direct-acting antiviral treatment in the prison setting: the SToP-C study","volume":"75","author":"Carson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024111411415409300_ciad127-B19","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/cid\/ciz693","article-title":"Low hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy","volume":"70","author":"Akiyama","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024111411415409300_ciad127-B20","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3018(22)00077-7","article-title":"Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression","volume":"9","author":"Hosseini-Hooshyar","year":"2022","journal-title":"Lancet HIV"},{"key":"2024111411415409300_ciad127-B21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis","volume":"72","author":"Hajarizadeh","year":"2020","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"2024111411415409300_ciad127-B22","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.2105\/AJPH.2013.301421","article-title":"Health care utilization patterns of homeless individuals in Boston: preparing for medicaid expansion under the affordable care act","volume":"103","author":"Bharel","year":"2013","journal-title":"Am J Public Health"},{"key":"2024111411415409300_ciad127-B23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42676","article-title":"Drug overdose mortality among people experiencing homelessness, 2003 to 2018","volume":"5","author":"Fine","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024111411415409300_ciad127-B24","author":"Department of Housing and Urban Development"},{"key":"2024111411415409300_ciad127-B25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S2468-1253(16)30182-0","article-title":"Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study","volume":"2","author":"Islam","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024111411415409300_ciad127-B26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2013.03.008","article-title":"Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C","volume":"59","author":"Marco","year":"2013","journal-title":"J Hepatol"},{"key":"2024111411415409300_ciad127-B27","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jhep.2016.01.001","article-title":"Hepatitis C reinfection after sustained virological response","volume":"64","author":"Midgard","year":"2016","journal-title":"J Hepatol"},{"key":"2024111411415409300_ciad127-B28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/jvh.13035","article-title":"High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme","volume":"26","author":"Schulkind","year":"2019","journal-title":"J Viral Hepat"},{"key":"2024111411415409300_ciad127-B29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2105\/AJPH.2021.306208","article-title":"Delivering preexposure prophylaxis to people who use drugs and experience homelessness, Boston, MA, 2018\u20132020","volume":"111","author":"Biello","year":"2021","journal-title":"Am J Public Health"},{"key":"2024111411415409300_ciad127-B30","article-title":"Patient and provider perspectives on a novel, low-threshold HIV PrEP program for people who inject drugs experiencing homelessness","author":"Bazzi","year":"2022","journal-title":"J Gen Intern Med"},{"key":"2024111411415409300_ciad127-B31","author":"Massachusetts Harm Reduction Commission"},{"key":"2024111411415409300_ciad127-B32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2468-1253(16)30075-9","article-title":"Hepatitis C treatment as prevention: evidence, feasibility, and challenges","volume":"1","author":"Hajarizadeh","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024111411415409300_ciad127-B33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S2468-1253(21)00077-7","article-title":"Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study","volume":"6","author":"Hajarizadeh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024111411415409300_ciad127-B34","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/joim.12740","article-title":"Treatment as prevention for hepatitis C (TraP Hep C)\u2014a nationwide elimination programme in Iceland using direct-acting antiviral agents","volume":"283","author":"Olafsson","year":"2018","journal-title":"J Intern Med"},{"key":"2024111411415409300_ciad127-B35","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.103019","article-title":"Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration","volume":"88","author":"Ward","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2024111411415409300_ciad127-B36","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians\u2019 views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs","volume":"51","author":"Asher","year":"2016","journal-title":"Subst Use Misuse"},{"key":"2024111411415409300_ciad127-B37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2468-1253(17)30284-4","article-title":"Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe","volume":"3","author":"Marshall","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024111411415409300_ciad127-B38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad127\/49678608\/ciad127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/1\/46\/50799036\/ciad127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/1\/46\/50799036\/ciad127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:38:38Z","timestamp":1731587918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/1\/46\/7069617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,4]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad127","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,3,4]]}}}